Coadministration has not been studied. Voriconazole is a strong inhibitor of CYP3A4 and may increase plasma concentrations of elvitegravir/cobicistat. Concentrations of voriconazole may also increase. When coadministration is required, an assessment of benefit/risk ratio is recommended to justify the use of voriconazole. Emtricitabine and tenofovir alafenamide do not interact with voriconazole metabolic pathway.